Integrin beta-1 (ITGB1) (ITGB1)

Integrin beta-1 (ITGB1), also known as CD29, is a ubiquitous transmembrane receptor subunit that pairs with at least 12 different alpha subunits to form the largest subfamily of integrin heterodimers (UniProt P05556). These receptors are fundamental to cell-extracellular matrix (ECM) adhesion and mediate bidirectional inside-out and outside-in signaling, influencing cell survival, differentiation, and migration (PubMed: 29143303). In oncology, ITGB1 is frequently upregulated and is a key driver of the cell adhesion-mediated drug resistance (CAM-DR) phenotype, as well as promoting epithelial-mesenchymal transition (EMT) and metastasis (PubMed: 30635431). Beyond cancer, ITGB1 is involved in fibrotic diseases and inflammatory processes, making it a versatile therapeutic target. Current pharmacological approaches include monoclonal antibodies like OS2966 and Volociximab, which aim to block ligand binding and inhibit downstream oncogenic signaling pathways such as FAK and PI3K/Akt (PubMed: 27535223).

Other names

CD29Fibronectin receptor subunit betaVery late antigen 4 subunit betaVLA-4 subunit betaGlycoprotein IIaGPIIaMSK12FNRB

Inhibition of ligand binding (e.g., fibronectin, collagen, laminin) to the integrin heterodimer, thereby blocking downstream intracellular signaling pathways such as Focal Adhesion Kinase (FAK), Src, and PI3K/Akt, which are essential for cell adhesion, migration, and survival (PubMed: 29143303, 27535223).